RecruitingNCT06234306

Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care

Sponsor

Copenhagen University Hospital at Herlev

Enrollment

500 participants

Start Date

Jan 1, 2024

Study Type

OBSERVATIONAL

Summary

Small bowel adenocarcinoma is a rare malignancy, and there is limited knowledge about its optimal clinical management and molecular background. The SBAMOL study is an observational biomarker study that aims to identify prognostic and predictive biomarkers. This effort is intended to lay the groundwork for personalized medicine tailored to this specific patient group.

Eligibility

Min Age: 18 Years

Inclusion Criteria1

Patients with histologically verified small bowel adenocarcinoma Patients older than 18 years

Exclusion Criteria2

Insufficient material for molecular testing Patients registered in Vævsanvendelsesregistret\&
Vævsanvendelsesregistret; refers to a central Danish registry where patients can opt out of allowing their biological material to be used for purposes other than their own disease management.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(3)

Department of Oncology, Aarhus University Hospital

Aarhus N, Denmark

Department Surgical Gastroenterology, Copenhagen University Hospital - Rigshospitalet

Copenhagen Ø, Denmark

Department of Oncology Copenhagen University Hospital - Herlev and Gentofte

Herlev, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06234306